UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)

·1h ago
Share:PostShare

Antiphospholipid syndrome (APS) is a serious autoimmune condition that mainly affects women of childbearing age (WoCBA) and can cause serious adverse pregnancy outcomes, with no therapies currently approved. The Breakthrough Therapy Designation (BTD) is supported by findings from the...

P

Pr Newswire

Original source

Read full story

ucb bd

Check live status on DownRightNow

Check status →

Related Stories

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer